82072-22-8

Usage

Uses

Used in Pharmaceutical Industry:
(3-(Bromomethyl)phenyl)methanol is used as a synthetic intermediate for the development of pharmaceuticals, contributing to the creation of new drugs and improving existing ones. Its unique structure and reactivity allow for the formation of diverse chemical entities with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, (3-(Bromomethyl)phenyl)methanol is utilized as a precursor in the synthesis of various agrochemicals, such as pesticides and herbicides. Its reactivity enables the production of compounds that can effectively control pests and weeds, thereby enhancing crop protection and yield.
Used in Organic Synthesis:
(3-(Bromomethyl)phenyl)methanol is employed as a reagent in organic synthesis, facilitating the preparation of a wide range of organic compounds. Its ability to react with different functional groups makes it a versatile building block for the creation of complex molecules with specific properties and applications.
Used in Medicinal Chemistry:
(3-(Bromomethyl)phenyl)methanol is used as a key component in the design and synthesis of new medicinal agents. Its unique chemical properties allow for the development of compounds with potential therapeutic effects, contributing to the advancement of treatments for various diseases and conditions.
Used in Material Chemistry:
In the field of material chemistry, (3-(Bromomethyl)phenyl)methanol is utilized for the synthesis of novel materials with specific properties. Its reactivity and structural features enable the creation of materials with potential applications in various industries, such as electronics, coatings, and adhesives.

Upstream product

• 6515-58-8 3-bromomethylbenzoic acid 
• 626-18-6 1,3-dimethanol benzene 
• 99-36-5 1-methoxycarbonyl-3-methylbenzene 
• 1129-28-8 3-methoxycarbonylbenzyl bromide 
• 626-15-3 1,3-bis-(bromomethyl)benzene 

Downstream Products

• 1155702-76-3 4-[3-(hydroxymethyl)benzyl]benzonitrile 
• 1365392-18-2 C₂₅H₃₅NO₅S 
• 494222-21-8 4-{[2-((2R)-2-{(1E,3S)-3-hydroxy-4-[3-(cyclopropoxymethyl)phenyl]but-1-enyl}-5-oxopyrrolidin-1-yl)ethyl]sulfanyl}butanoic acid 
• 1365392-97-7 methyl {3-[(vinyloxy)methyl]phenyl}acetate 
• 1365393-00-5 methyl {3-[(cyclopropyloxy)methyl]phenyl}acetate 
• 1365392-50-2 dimethyl 3-[3-(cyclopropoxymethyl)phenyl]-2-oxopropanephosphonate 
• 1419326-94-5 trans-[PtBr₂Me₂(CH₂-3-C₆H₄-CH₂OH)(4,4'-bis(ethoxycarbonyl)-2,2'-bipyridine)] 
• 69383-72-8 3-(N,N-Dimethylaminomethyl)benzenemethanol 
• 91271-56-6 m-Diethylaminomethylbenzyl alcohol 

Relevant academic research and scientific papers

Galantamine-curcumin hybrids as dual-site binding acetylcholinesterase inhibitors

Galantamine (GAL) and curcumin (CU) are alkaloids used to improve symptomatically neurodegenerative conditions like Alzheimer's disease (AD). GAL acts mainly as an inhibitor of the enzyme acetylcholinesterase (AChE). CU binds to amyloid-beta (Aβ) oligomers and inhibits the formation of Aβ plaques. Here, we combine GAL core with CU fragments and design a combinatorial library of GAL-CU hybrids as dual-site binding AChE inhibitors. The designed hybrids are screened for optimal ADME properties and BBB permeability and docked on AChE. The 14 best performing compounds are synthesized and tested in vitro for neurotoxicity and anti-AChE activity. Five of them are less toxic than GAL and CU and show activities between 41 and 186 times higher than GAL.

PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS

Disclosed in the present application is a compound of formula (I) as defined herein as well as a pharmaceutical composition comprising said compound. Further disclosed in the present application is the use of such pharmaceutical compositions for treating diseases, namely inter alia for use in the treatment of cancer, metabolic, inflammatory, autoimmune and viral diseases. The compounds disclosed herein are inhibitors of MNK1 and/or MNK2 kinases.

Aromatic PCN palladium pincer complexes. Probing the hemilability through reactions with nucleophiles

A series of unsymmetrical PCN pincer ligands (1-(3-((di-tert-butylphosphino)methyl)phenyl)-N,N-dialkylmethanamine) were cyclometalated with palladium to generate a series of new PCN supported Pd(II) chloro complexes, (PCN)PdCl (4-6), where alkyl = methyl, ethyl, and n-propyl, which were fully characterized by NMR spectroscopy and X-ray crystallography. The N,N-dimethyl complex 4 reacts with methyl lithium to give the corresponding methyl and dimethyl complexes (PCN)PdMe (12) and Li[(PCN)PdMe2] (13), which could not be isolated but were characterized in solution. The substitution reactions of (PCN)PdCl (4-6) with iodide to form the corresponding iodo complexes (PCN)PdI (7-9) were investigated by use of UV-vis stopped-flow spectrophotometry. The experiments were performed in methanol over a temperature range from 293 to 325 K. The reactions are reversible and were shown to proceed exclusively via the solvento complex in two reversible consecutive steps. Activation parameters for both the forward and reverse reactions were determined, and they, together with reactivity trends, support an associative pathway. No displacement of the nitrogen donor was detected, and overall this points to a limited hemilability of the ligands on palladium.

METHOD OF CONTROLLING LACTATE PRODUCTION WITH PIPERDINE-DIONE DERIVATIVES

The invention provides novel compounds having the general formula: and tautomers and pharmaceutically acceptable salts thereof, wherein A1, A2, A3, A4, R1, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds and methods of using the compounds.

PIPERIDINE-DIONE DERIVATIVES

The invention provides novel compounds having the general formula (I) and tautomers and pharmaceutically acceptable salts thereof, wherein A1, A2, A3, A4, R1, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds and methods of using the compounds.

AROMATIC RING COMPOUND

Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

Discovery of orally available 8-aza-5-thiaProstaglandin E1 analogs as highly selective EP4 agonists

Analogs 8-aza-16-aryl prostaglandin E1 (PGE1) and 8-aza-5-thia-16-arylPGE1 were synthesized and evaluated with respect to their subtype receptor affinity and EP4 agonist activity for the purposes of identifying sub-type- selective EP

Nucleophilic de-coordination and electrophilic regeneration of "hemilabile" pincer-type complexes: Formation of anionic dialkyl, diaryl, and dihydride PtII complexes bearing no stabilizing π-acceptors

Novel anionic dialkyl, diaryl, and dihydride platinum(II) complexes based on the new πlong-armπ hemilabile PCN-type ligand C6H 4[CH2P(tBu)2](CH2) 2N(CH3)2 with the general formula Li + [Pt(PCN)(R)2]- (R = Me (4), Ph (6) and H (9)) were prepared by reaction of [Pt(PCN)(R)] complexes (obtained from the corresponding chlorides) with an equivalent of RLi, as a result of the opening of the chelate ring. Alkylating agents based on other metals produce less stable products. These anionic d8 complexes are thermally stable although they bear no stabilizing π acceptors. They were characterized by 1H, 31P{1H}, 13C, and 7Li NMR spectroscopy; complex 9 was also characterized by single crystal X-ray crystallography, showing that the Li + ion is coordinated to the nitrogen atom of the open amine arm and to the hydride ligand (trans to the P atom) of a neighboring molecule (H-Li = 2.15 A), resulting in a dimeric structure. Complexes 4 and 9 exhibit high nucleophilic reactivity, upon which the pincer complex is regenerated. Reaction of 4 with water, methyl iodide, and iodobenzene resulted in the neutral complex [Pt(PCN)(CH3)] (3) and methane, ethane, or toluene, respectively. Labeling studies indicate that the reaction proceeds by direct electrophilic attack on the metal center, rather than attack on the alkyl ligand. The anionic dihydride complex 9 reacted with water and methyl iodide to yield [Pt(PCN)(H)] (8) and H2 or methane, respectively.

BENZYLIDENE RHODANINES

This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with . beta.-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.

Esters of monic acid A useful as antibacterial and antimycoplasmal agents

Compounds of formula (II): STR1 wherein R is C1-20 alkyl; C3-8 cycloalkyl; C3-20 alkenyl; aralkyl; cycloalkylalkyl; heterocyclyl or heterocyclylalkyl; each being substituted with formyl; STR2 have activity against human and veterinary bacteria and mycoplasma. They may be produced by conventional methods and are used in conventional formulations.